Most importantly, we demonstrate that RAC1P29S remains constitutively active in IGR1 human melanoma cells even under serum-starved conditions and that its activation can be significantly reduced by the pharmacological inhibition of DOCK2 with CPYPP. Here, DOCK2 is linked to melanoma.